Kimberly Ann Pitkin, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2178 East Seneca Street, Ovid, NY 14521 Phone: 607-227-8847 |
Marnie Pealo, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 7150 Main St, Ovid, NY 14521 Phone: 607-403-0065 Fax: 607-403-0093 |
Laurie L Guinan, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 7150 Main St, Ovid, NY 14521 Phone: 607-403-0065 |
News Archive
'Mindfulness', the process of learning to become more aware of our ongoing experiences, increases well-being in adolescent boys, a new study reports. Researchers from the University of Cambridge analyzed 155 boys from two independent UK schools, Tonbridge and Hampton, before and after a four-week crash course in mindfulness. After the trial period, the 14 and 15 year-old boys were found to have increased well-being, defined as the combination of feeling good (including positive emotions such as happiness, contentment, interest and affection) and functioning well.
FICO, the leading provider of analytics and decision management technology, today announced the general availability of FICO™ Insurance Fraud Manager 3.1. With this newest version, FICO continues to build upon and strengthen its proven solution for detecting healthcare claim fraud, abuse and errors before claims are paid, and also for identifying suspicious providers as soon as aberrant patterns emerge.
For decades, American Baby Boomers have been characterized as a bloc of people who think and act as one monolithic generation. However, recent data from the MetLife Mature Market Institute®, show that Young, Middle and Older Boomers grew up during disparate "eras" and are now at different stages in their lives. They should, perhaps, be treated as separate demographic groups.
"The U.S. Food and Drug Administration on Monday approved Johnson & Johnson's drug to treat a form of resistant tuberculosis that is uncommon in the U.S. but growing globally," the Wall Street Journal reports.
Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 16th Annual Connective Tissue Oncology Society (CTOS) Meeting taking place in Paris, France from November 11 to 13, 2010.
› Verified 9 days ago